MX2011002783A - Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos. - Google Patents

Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos.

Info

Publication number
MX2011002783A
MX2011002783A MX2011002783A MX2011002783A MX2011002783A MX 2011002783 A MX2011002783 A MX 2011002783A MX 2011002783 A MX2011002783 A MX 2011002783A MX 2011002783 A MX2011002783 A MX 2011002783A MX 2011002783 A MX2011002783 A MX 2011002783A
Authority
MX
Mexico
Prior art keywords
rapamycin
carbonic ester
preparations
pharmaceutical compositions
ester analogues
Prior art date
Application number
MX2011002783A
Other languages
English (en)
Inventor
Fajun Nan
Jian Ding
Jianping Zuo
Linqian Yu
Linghua Meng
Yangming Zhang
Na Yang
Min Gu
Original Assignee
Emy Of Sciences Shanghai Inst Of Materia Medica Chinese Acad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emy Of Sciences Shanghai Inst Of Materia Medica Chinese Acad filed Critical Emy Of Sciences Shanghai Inst Of Materia Medica Chinese Acad
Publication of MX2011002783A publication Critical patent/MX2011002783A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Los rapálogos de la fórmula 1, las sales farmacéuticamente aceptables, las composiciones farmacéuticas y los métodos de preparación y usos de las mismas, los rapálogos tienen la fórmula I y pueden ser usados como un medicamento en contra del tumor. Comparando con la rapamicina, los rapálogos de la presente invención exhiben una solubilidad en agua mejorada, y propiedades farmacológicas y farmacocinéticas mejoradas mediante el introducir un grupo polar e hidrofílico tal como hidroxilo.
MX2011002783A 2008-09-18 2009-09-17 Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos. MX2011002783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810200073XA CN101676291B (zh) 2008-09-18 2008-09-18 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
PCT/CN2009/001042 WO2010031251A1 (zh) 2008-09-18 2009-09-17 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
MX2011002783A true MX2011002783A (es) 2011-09-01

Family

ID=42029020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011002783A MX2011002783A (es) 2008-09-18 2009-09-17 Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos.

Country Status (8)

Country Link
US (1) US8455510B2 (es)
EP (1) EP2351757A4 (es)
JP (1) JP5394493B2 (es)
CN (1) CN101676291B (es)
BR (1) BRPI0913726A2 (es)
CA (1) CA2737355C (es)
MX (1) MX2011002783A (es)
WO (1) WO2010031251A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131019A1 (en) * 2011-04-01 2012-10-04 Sandoz Ag Regioselective acylation of rapamycin at the c-42 position
KR102112002B1 (ko) 2011-04-29 2020-05-18 셀렉타 바이오사이언시즈, 인크. 치료적 단백질에 대해 면역 반응을 감소시키는 관용원성 합성 나노운반체
KR101444693B1 (ko) * 2011-06-06 2014-09-26 아버 테라퓨틱스 엘엘씨 암 화학요법제의 산에 불안정한 친유성 전구약물
CN105339012A (zh) * 2013-05-03 2016-02-17 西莱克塔生物科技公司 降低i型和iv型超敏反应的致耐受性合成纳米载体的局部伴随施用
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
CA2957800A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
ES2865375T3 (es) 2014-11-05 2021-10-15 Selecta Biosciences Inc Métodos y composiciones relacionadas con nanovehículos sintéticos con rapamicina en un estado sobresaturado estable
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US20170258927A1 (en) 2016-03-11 2017-09-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CN109922819A (zh) 2016-09-27 2019-06-21 西莱克塔生物科技公司 用于治疗癌症的重组免疫毒素
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2019126374A1 (en) * 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
EP3823676A1 (en) 2018-07-16 2021-05-26 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
EP3976802A1 (en) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
US20210154324A1 (en) 2019-10-21 2021-05-27 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
JP2023501457A (ja) 2019-11-08 2023-01-18 セレクタ バイオサイエンシーズ インコーポレーテッド ペグ化ウリカーゼの処方物および用量
CA3166908A1 (en) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Lipid prodrugs of neurosteroids
CN115379839A (zh) 2020-02-26 2022-11-22 西莱克塔生物科技公司 使用包含免疫抑制剂的合成纳米载体的方法和组合物
BR112022018070A2 (pt) 2020-03-11 2022-10-25 Selecta Biosciences Inc Métodos e composições relacionados a nanoveículos sintéticos
MX2022012916A (es) 2020-04-14 2023-01-30 Selecta Biosciences Inc Métodos y composiciones para inducir la autofagia.
CN116568329A (zh) 2020-11-04 2023-08-08 西莱克塔生物科技公司 用于降低针对免疫球蛋白蛋白酶的免疫应答的组合物
CN114762696B (zh) * 2021-01-12 2024-01-30 上海科技大学 低氘水的用途及相关产品
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
JPH08509499A (ja) * 1993-04-23 1996-10-08 アボツト・ラボラトリーズ ラパマイシン結合体及び抗体
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1319008T3 (da) * 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP1648900A4 (en) * 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
SG152234A1 (en) * 2004-04-14 2009-05-29 Wyeth Corp Regiospecific synthesis of rapamycin 42-ester derivatives
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters

Also Published As

Publication number Publication date
EP2351757A1 (en) 2011-08-03
CA2737355A1 (en) 2010-03-25
JP2012502930A (ja) 2012-02-02
EP2351757A4 (en) 2012-05-02
BRPI0913726A2 (pt) 2015-10-13
CA2737355C (en) 2015-01-13
CN101676291A (zh) 2010-03-24
US20110166172A1 (en) 2011-07-07
JP5394493B2 (ja) 2014-01-22
CN101676291B (zh) 2012-05-09
WO2010031251A1 (zh) 2010-03-25
US8455510B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
MX2011002783A (es) Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos.
TW200626558A (en) Indazolone derivatives
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
UA94052C2 (uk) Похідні піридазину
MX2010005824A (es) Derivados de aminotiazol.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MY153921A (en) Aminopyrazole derivatives
IN2012DN03337A (es)
IN2012DN03182A (es)
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
TW200616976A (en) Pyrimidine derivatives
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
EP3626253A3 (en) Stable formulations of linaclotide
MX2010005714A (es) Compuestos de piridina.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
WO2009063222A3 (en) Solid compositions
TW200740764A (en) Pyrazolone derivatives
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
MX2009003169A (es) Derivados de sulfonamida.
WO2010056039A3 (en) Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration